FibroBiologics, Inc. announced a public offering on March 31, 2026, for 1,028,788 shares of common stock at $1.32 each, aiming to raise approximately $2.5 million net after fees, with potential additional proceeds of approximately $3 million from warrants, contingent on stockholder approval.